Results 211 to 220 of about 17,468,048 (391)

Safety and Effectiveness of Emicizumab in People With Haemophilia A Enrolled in the ATHN 7 Haemophilia Natural History Study

Haemophilia, EarlyView.
ABSTRACT Background The Natural History Study of the Safety, Effectiveness, and Practice of Treatment for People with Haemophilia (ATHN 7) monitors use of contemporary haemophilia therapies, including emicizumab, a bispecific antibody substituting for activated factor (F)VIII in people with haemophilia A (HA).
Tyler W. Buckner, Shannon L. Carpenter, Nabil Daoud, Christine L. Kempton, Lucy Lee, Lynn Malec, Thomas W. McLean, Paul Morton, Carrie O'Neill, Janice M. Staber, Michael Wang, Stacy E. Croteau, Michael Recht   +12 more
wiley   +1 more source

Impact of Lupus Anticoagulant on INR Using Recombinant Prothrombin Time Reagent. [PDF]

Am J Case Rep
Kamal F, Othman HR.
europepmc   +1 more source

Case report of recurrent bleeding in an infant with isolated prolonged prothrombin time due to congenital factor VII deficiency---a riddle solved. [PDF]

J Family Med Prim Care, 2022
Ganguly M, Sutradhar S, Rajbangshi A, Pattnaik A, Maiti D.   +4 more
europepmc   +1 more source

Post‑Marketing Surveillance of the Safety and Effectiveness of Emicizumab in Japanese Patients With Congenital Haemophilia A With Inhibitors

Haemophilia, EarlyView.
ABSTRACT Introduction The bispecific monoclonal antibody emicizumab was approved for prophylactic treatment of congenital haemophilia A (HA) in Japan in 2018. Aim To monitor long‐term safety and effectiveness of emicizumab, including appropriate concomitant use of bypassing agents (BPAs), in Japanese patients with congenital HA with inhibitors who ...
Midori Shima, Katsuyuki Fukutake, Masanori Matsumoto, Yoshihiko Sugimura, Chiaki Sugita, Lyu Ji, Mika Kawano, Tadashi Matsushita   +7 more
wiley   +1 more source

Fully printed prothrombin time sensor for point-of-care testing. [PDF]

Biosens Bioelectron, 2021
Williams NX, Carroll B, Noyce SG, Hobbie HA, Joh DY, Rogers JG, Franklin AD.   +6 more
europepmc   +1 more source

A Novel Prothrombin Time Assay for Assessing the Anticoagulant Activity of Oral Factor Xa Inhibitors

Clinical and applied thrombosis/hemostasis, 2013
Y. Barrett, Zhaoqing Wang, R. Knabb
semanticscholar   +1 more source

Clinical Characteristics and Long‐Term Prognosis of Primary Biliary Cholangitis in Japan: Results of the 2nd‐Generation Nationwide Survey

Hepatology Research, EarlyView.
We have established the 2nd‐generation nationwide survey of PBC in Japan. Our analyses of the survey result not only highlight the demographical trend in Japanese PBC patients over time; they also validate the previously described risk factors for the patients' prognoses.
Yuki Kugiyama, Masanori Abe, Tadashi Namisaki, Hitoshi Yoshiji, Kazumichi Abe, Hiromasa Ohira, Ryosaku Shirahashi, Keiji Yokoyama, Atsushi Fukunaga, Kazuhito Kawata, Masahiro Umemura, Akira Honda, Tadashi Ikegami, Shiho Miyase, Toshiaki Nakano, Atsumasa Komori, Atsushi Tanaka, on behalf of the Japan PBC Study Group   +17 more
wiley   +1 more source

Transient shortening of activated partial thromboplastin time and prothrombin time associated with transient global amnesia. [PDF]

Postep Psychiatr Neurol
Dziubek D, Dziubek K, Stodolak M.
europepmc   +1 more source

Effect of the reaction temperature on the prothrombin time and the apparent International Normalized Ratio determined with International Standards for thromboplastins. [PDF]

Int J Lab Hematol, 2022
Van Den Besselaar AMHP, Cobbaert CM.
europepmc   +1 more source

Anticoagulant Evaluation of Momordica charantia Fruit Flesh Extract on Prothrombin Time and Activated Partial Prothrombin Time Test

, 2023
Norhaida Che Azmi, Anis Athiqah Suhimi, Tuan Syaripah Atiqah Najwa Tuan Yahya   +2 more
openalex   +1 more source